Summary:
Olympian Clinical Research is looking for men and women with moderate to severe plaque psoriasis to participate in a research study. The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab (Stelara) in subjects with moderate-to-severe plaque psoriasis.
Qualified Participants Must:
• Be between 18 and 80 years of age
•
Have been diagnosed with plaque-type psoriasis with or without psoriatic arthritis for at least 6 months
•
Have a current diagnosis of moderate to severe plaque-type psoriasis
Qualified Participants May Receive:
Investigational medication or placebo, study-related tests, exams, medical care related to the study from board-certified physicians and reimbursement for expenses associated with study visits, such as travel expenses.